Veranex’s Post

Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model A new article has been published in the Journal Small Science: https://bit.ly/3RQk88z

Non-surgical interventional treatments for knee osteoarthritis: The need for different perspectives, cross-specialty collaboration, and preclinical and translational research https://bit.ly/49HiVqU #OA #Osteoarthritis #KneeOsteoarthritis

Monica Perez, PT, PhD, Shirley Ryan AbilityLab research scientist, was featured in an NBC Chicago story about a first-of-its-kind clinical trial underway at Shirley Ryan AbilityLab to test NVG-291, an investigational drug that targets the body's natural inhibitors of repair. NVG-291 has demonstrated the ability to promote axonal regeneration, remyelination, plasticity and improved function in preclinical studies in spinal cord injury. Watch the full story and learn more about study eligibility and enrollment: bit.ly/4dQwB5c #spinalcordinjury #SCI #clinicalresearch #researchstudy #SCIawarenessmonth #spinalcordinjuryawarenessmonth

The Osteoarthritis Research Society International Congress 2024 will take place in Vienna, Austria, from April 18 to 21. Our Chief Medical Officer, Professor francis berenbaum, is scheduled to deliver an oral presentation on Friday, April 19, 2024. His presentation is titled IN-MOTION: "Pioneering a Phase 2b Clinical Trial Tailored for Inflamed Phenotypes in Knee Osteoarthritis with Intraarticular Liraglutide." Also, Coralie Meurot, our preclinical research scientist, will present her poster titled "Intra-articular Administration of Liraglutide Mitigates Synovial Tissue Alteration and Cartilage Degradation in Preclinical Osteoarthritis Models" during the poster presentation session. #4P004 #clinicaltrial #OARSI #Biotech.

☑️ AngioDynamics' NanoKnife System secures CPT codes for prostate and liver treatments, streamlining reimbursement for irreversible electroporation (IRE) ablation procedures. ☑️ Thermo Fisher Scientific's Oncomine gains FDA approval as a brain tumor diagnostic, aiding in the identification of patients eligible for treatment with Servier’s Voranigo. ☑️ GE HealthCare launches the genAI CareIntellect platform, using generative AI to aggregate multimodal oncology data and summarize clinical notes and reports. ☑️ iRhythm Technologies, Inc. obtains 510(k) clearance for updates to its Zio device after receiving an FDA warning letter in May 2024 for regulatory violations. ☑️ Oxford Medical Group Products reports positive safety data from first-in-human trials for its dual-polymer hydrogel stomach implant, targeting mechanical weight loss with a pivotal trial planned. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr

Recently, Argenica released results from a pilot study assessing the efficacy of ARG-007 in a ferret preclinical model of mild to moderate traumatic brain injury (modTBI). Based on the positive results shown in this study, the Company will investigate the performance of ARG-007 in a larger scale ferret preclinical study to further validate this data. Taken together with previous rodent studies, this will provide Argenica with a robust preclinical data set on the efficacy of ARG-007 in TBI. Learn more or read the full announcement ➡ https://lnkd.in/evuvHHN7 #ASX #AGN #TBI #traumaticbraininjury #biotechnology #lifesciences #ARG007

Dive into our latest blog where we dissect the diverse response criteria based on imaging endpoints. We’re comparing their pros and cons and exploring how they can be improved. Focusing on structural imaging like CT and MRI versus functional imaging in PET scans, we explore how each method may impact the evaluation of new medical treatments. Click here to read: https://lnkd.in/ggQi_reM #ImaginAb #immunooncology #CD8ImmunoPET #biotech #pharma #theranostics #PETCT #nuclearmedicine #clinicaltrials Matthew Hoover

☑️ Lungpacer Medical received FDA premarket approval for its AeroPace neurostimulation system, which is designed to strengthen the diaphragm in patients on mechanical ventilation. ☑️ COPAN Diagnostics, Inc. secures FDA clearance for its urine collection and transport device, simplifying preservation by eliminating precise fill lines and mixing. ☑️ AngioDynamics secures FDA clearance for its NanoKnife system, designed for prostate tissue ablation in intermediate-risk cancer patients. ☑️ SetPoint Medical submits its neuroimmune modulation device for FDA premarket approval (PMA). ☑️ Adaptive Biotechnologies Corp. unveils data from its MRD assessment test, which quantifies malignant DNA sequences in blood cancer treatment. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr

As researchers continue to look for new ways to test therapeutics in vitro, the field of biomedical engineering is offering new microphysiological systems that can reduce the need for animal models. Hear from Jeffrey Borenstein, Director of our Biomedical Engineering Centre, as he explains how it works, ways to expedite its access and the benefits they will ultimately bring to patients. Listen: https://lnkd.in/eKM33_eu #biomedical #therapeutics #microphysiological #organonchip Charles River Laboratories

MedChemAdvent 21. 𝐅𝐥𝐮𝐫𝐩𝐢𝐫𝐢𝐝𝐚𝐳 (18𝐅) (brand name Flyrcado) Flurpiridaz is a cyclotron-produced radioactive diagnostic agent for use with positron emission tomography (PET) myocardial perfusion imaging (MPI) to evaluate for myocardial ischemia and infarction. It is a first-of-its-kind imaging tracer for PET scans that helps assess the perfusion of heart muscle cells and gives a clearer picture of blocked arteries in the heart and any damage to cardiac tissue. Flurpiridaz was discovered by Lantheus (formerly known as Bristol-Myers Squibb Medical Imaging) and GE HealthCare did further development. The compound is a Mitochondrial Complex I (MC-I) inhibitor. It demonstrates rapid uptake by cardiomyocytes with high first-pass extraction fraction by the heart and slow washout due to high specificity for and potent binding to MC-1. During the discovery of various pyridazinone analogs, a structure-activity relationship (SAR) assessment indicated a preference for the fluorine label to be incorporated on an alkyl side chain rather than directly on the heterocyclic moiety. See the paper on Flurpiridaz discovery here: https://lnkd.in/e2JVeggu 𝘐𝘯 𝘵𝘩𝘦𝘴𝘦 𝘭𝘢𝘴𝘵 𝘥𝘢𝘺𝘴 𝘰𝘧 2024 𝘥𝘶𝘳𝘪𝘯𝘨 𝘈𝘥𝘷𝘦𝘯𝘵, 𝘸𝘦 𝘸𝘰𝘶𝘭𝘥 𝘭𝘪𝘬𝘦 𝘵𝘰 𝘳𝘦𝘤𝘢𝘭𝘭 𝘴𝘰𝘮𝘦 𝘥𝘳𝘶𝘨 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘦𝘴 𝘵𝘩𝘢𝘵 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘍𝘋𝘈 𝘪𝘯 2024. 𝘌𝘢𝘤𝘩 𝘥𝘢𝘺 𝘶𝘯𝘵𝘪𝘭 𝘊𝘩𝘳𝘪𝘴𝘵𝘮𝘢𝘴 𝘸𝘦 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦𝘮 𝘪𝘯 𝘰𝘶𝘳 𝘔𝘦𝘥𝘊𝘩𝘦𝘮𝘈𝘥𝘷𝘦𝘯𝘵. 𝘌𝘯𝘫𝘰𝘺! #MedChemAdvent #DrugDiscovery #MedicinalChemistry #FDA #Flurpiridaz #PET #Fluorine